Wall Street analyst estimates for GE HealthCare Technologies Inc. (GEHC): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients.
Consensus price target
$81.14 (+2 % vs price $79.55)
between $67.00 and $95.00 · 3 targets published in the last quarter
Closing price, Nov 2
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $21.9B | $21.7B – $21.9B | $5.01 | 12 |
| 2027E | $22.9B | $22.8B – $23.0B | $5.50 | 13 |
| 2028E | $24.1B | $23.7B – $24.7B | $6.11 | 9 |
Figures in USD · consensus as of November 2, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 11 |
| Hold | 8 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 19 |
| Avg rating (−2 sell to +2 buy) | 0.58 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2027-02-03 | $1.55 | ||
| 2026-10-28 | $1.34 | $1.20 | +11.7% |
| 2026-07-29 | $1.13 | $1.04 | +8.7% |
| 2026-04-29 | $0.99 | $1.04 | -4.8% |
| 2026-02-04 | $1.44 | $1.40 | +2.9% |
| 2025-10-29 | $1.07 | $1.05 | +1.9% |
| 2025-07-30 | $1.06 | $0.92 | +15.5% |
| 2025-04-30 | $1.01 | $0.91 | +10.5% |
Valuation Ratios
| P/E Ratio | 20.77 |
| Price / Book | 3.10 |
| Dividend Yield | 0.18% |
Income Statement (10y)
| Year | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|
| Revenue | $16.63B | $17.16B | $17.59B | $18.34B | $19.55B | $19.67B | $20.62B |
| Cost of Revenue | $10.09B | $10.40B | $10.41B | $11.16B | $11.63B | $11.47B | $12.38B |
| Gross Profit | $6.55B | $6.77B | $7.17B | $7.18B | $7.92B | $8.21B | $8.25B |
| Research & Development | $833.0M | $810.0M | $816.0M | $1.03B | $1.21B | $1.31B | $1.26B |
| Selling, General & Admin | $3.59B | $3.24B | $3.56B | $3.63B | $4.28B | $4.27B | $4.22B |
| Operating Expenses | $4.42B | $4.05B | $4.38B | $4.66B | $5.49B | $5.58B | $5.49B |
| Operating Income | $2.12B | $2.72B | $2.79B | $2.52B | $2.44B | $2.62B | $2.76B |
| EBITDA | $2.84B | $3.41B | $3.54B | $3.17B | $3.51B | $3.67B | $3.79B |
| Interest Expense | $88.0M | $66.0M | $40.0M | $86.0M | $542.0M | $505.0M | $450.0M |
| Pre-tax Income | $2.09B | $2.71B | $2.88B | $2.51B | $2.36B | $2.58B | $2.77B |
| Income Tax | $410.0M | $652.0M | $600.0M | $563.0M | $743.0M | $531.0M | $614.0M |
| Net Income | $1.52B | $13.85B | $2.25B | $1.92B | $1.57B | $1.99B | $2.08B |
| EPS | $3.35 | $4.41 | $4.90 | $4.22 | $3.04 | $4.37 | $4.56 |
| EPS (Diluted) | $3.35 | $4.41 | $4.90 | $4.22 | $3.02 | $4.34 | $4.55 |
| Shares Outstanding (Diluted) | 454.7 M | 454.7 M | 454.7 M | 453.9 M | 458.0 M | 459.0 M | 460.3 M |
Price
| Price | $79.55 (closing price, November 2, 2026) |
| Market Cap | $36.0B |
| Exchange | NASDAQ |
| Country | US |
Related companies: BSX · ABT · SYK · MDT · PHG
Explore sector: Healthcare · Medical - Devices
More sections of GEHC: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks